Kymera Therapeutics logo

Kymera Therapeutics share price today

(KYMR)

Kymera Therapeutics share price is $40.66 & ₹3,455.12 as on 21 Dec 2024, 2.30 'hrs' IST

$40.66

1.52

(3.88%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Kymera Therapeutics share price in Dollar and Rupees. Guide to invest in Kymera Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Kymera Therapeutics. Get details on the Indian mutual funds that are investing in Kymera Therapeutics. Get Analyst recommendations and forecasts along with all the Kymera Therapeutics's financials.

Kymera Therapeutics share price movements

  • Today's Low: $38.32
    Today's High: $40.76

    Day's Volatility :5.99%

  • 52 Weeks Low: $22.35
    52 Weeks High: $53.27

    52 Weeks Volatility :58.04%

Kymera Therapeutics Returns

PeriodKymera Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-18.65%
-11.1%
0.0%
6 Months
29.28%
-6.0%
0.0%
1 Year
51.49%
2.7%
0.0%
3 Years
-34.18%
0.6%
-19.7%

Kymera Therapeutics Key Statistics

in dollars & INR

Previous Close
$39.14
Open
$38.66
Today's High
$40.76
Today's Low
$38.32
Market Capitalization
$2.5B
Today's Volume
$1.0M
52 Week High
$53.27
52 Week Low
$22.35
Revenue TTM
$87.6M
EBITDA
$-190.5M
Earnings Per Share (EPS)
$-2.34
Profit Margin
-191.26%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-26.0%

How to invest in Kymera Therapeutics from India?

It is very easy for Indian residents to invest directly in Kymera Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Kymera Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Kymera Therapeutics or KYMR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Kymera Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Kymera Therapeutics shares which would translate to 0.021 fractional shares of Kymera Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Kymera Therapeutics, in just a few clicks!

Returns in Kymera Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Kymera Therapeutics investment value today

Current value as on today

₹1,53,686

Returns

₹53,686

(+53.69%)

Returns from Kymera Therapeutics Stock

₹51,490 (+51.49%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Kymera Therapeutics

-38%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Kymera Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 22, 2024. -38% less investors are searching Kymera Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Kymera Therapeutics

  • T. Rowe Price Associates, Inc.

    10.26%

  • Baker Bros Advisors LP

    9.26%

  • Bvf Inc

    7.97%

  • FMR Inc

    7.89%

  • Vanguard Group Inc

    7.34%

  • Wellington Management Company LLP

    7.13%

Analyst Recommendation on Kymera Therapeutics

Buy

    69%Buy

    30%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Kymera Therapeutics(by analysts ranked 0 to 5 stars)

Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
15
15
Hold
7
7
6
Sell
0
0
0

Analyst Forecast on Kymera Therapeutics

What analysts predicted

Upside of 44.46%

Current:

$40.66

Target:

$58.74

Insights on Kymera Therapeutics

  • Price Movement

    In the last 1 year, KYMR stock has moved up by 60.7%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 25.65M → 3.74M (in $), with an average decrease of 85.4% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -42.06M → -62.48M (in $), with an average decrease of 48.6% per quarter
  • KYMR vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 53.7%

Kymera Therapeutics Technicals Summary

Sell

Neutral

Buy

Kymera Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Kymera Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kymera Therapeutics Inc
-9.6%
29.28%
51.49%
-34.18%
22.25%
Regeneron Pharmaceuticals, Inc.
-5.73%
-34.03%
-17.38%
12.23%
86.41%
Biontech Se
4.48%
30.56%
7.97%
-55.71%
237.85%
Alnylam Pharmaceuticals, Inc.
-0.55%
10.11%
28.37%
26.29%
108.55%
Vertex Pharmaceuticals Incorporated
-11.79%
-16.36%
-2.55%
77.79%
80.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kymera Therapeutics Inc
NA
NA
NA
-2.84
-0.26
-0.15
NA
13.79
Regeneron Pharmaceuticals, Inc.
17.51
17.51
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.17
0.55
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kymera Therapeutics Inc
Buy
$2.5B
22.25%
NA
-191.26%
Regeneron Pharmaceuticals, Inc.
Buy
$77.8B
86.41%
17.51
33.61%
Biontech Se
Buy
$26.7B
237.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.8B
108.55%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$102.1B
80.12%
32.84
-4.51%

Kymera Therapeutics Dividend announcements

  • Kymera Therapeutics Earnings

    Kymera Therapeutics’s price-to-earnings ratio stands at None

    Read More

About Kymera Therapeutics

kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.
Organization
Kymera Therapeutics
Employees
184
CEO
Dr. Bruce L. Booth DPHIL, Ph.D.
Industry
Health Technology

Management People of Kymera Therapeutics

NameTitle
Dr. Bruce L. Booth DPHIL, Ph.D.
Co-Founder & Independent Chairman
Dr. Nello Mainolfi M.D., Ph.D.
Co-Founder, President, CEO & Director
Mr. Bruce N. Jacobs CFA
Chief Financial Officer
Dr. Jeremy G. Chadwick Ph.D.
Chief Operating Officer
Ms. Ellen V. Chiniara Esq., J.D.
Chief Legal Officer & Corporate Secretary
Dr. Jared A. Gollob M.D.
Chief Medical Officer
Ms. Karen Weisbach
Head of People & Culture
Dr. Juliet Williams B.A Ph.D.
Head of Research

Important FAQs about investing in Kymera Therapeutics from India :

What is Kymera Therapeutics share price today?

Kymera Therapeutics share price today stands at $40.66, Open: $38.66 ; Previous Close: $39.14 ; High: $40.76 ; Low: $38.32 ; 52 Week High: $53.27 ; 52 Week Low: $22.35. The stock opens at $38.66, after a previous close of $39.14. The stock reached a daily high of $40.76 and a low of $38.32, with a 52-week high of $53.27 and a 52-week low of $22.35.

Can Indians buy Kymera Therapeutics shares?

Yes, Indians can invest in the Kymera Therapeutics (KYMR) from India.

With INDmoney, you can buy Kymera Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Kymera Therapeutics at zero transaction cost.

How can I buy Kymera Therapeutics shares from India?

It is very easy to buy Kymera Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Kymera Therapeutics be purchased?

Yes, you can buy fractional shares of Kymera Therapeutics with INDmoney app.

What are the documents required to start investing in Kymera Therapeutics stocks?

To start investing in Kymera Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Kymera Therapeutics

Today’s highest price of Kymera Therapeutics (KYMR) is $40.76.

Today’s lowest price of Kymera Therapeutics (KYMR) is $38.32.

What is today's market capitalisation of Kymera Therapeutics

Today's market capitalisation of Kymera Therapeutics KYMR is 2.5B

What is the 52 Week High and Low Range of Kymera Therapeutics

  • 52 Week High

    $53.27

  • 52 Week Low

    $22.35

What are the historical returns of Kymera Therapeutics?

  • 1 Month Returns

    -9.6%

  • 3 Months Returns

    29.28%

  • 1 Year Returns

    51.49%

  • 5 Years Returns

    22.25%

Who is the Chief Executive Officer (CEO) of Kymera Therapeutics

Dr. Bruce L. Booth DPHIL, Ph.D. is the current Chief Executive Officer (CEO) of Kymera Therapeutics.